Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutic Com (NQ: SAGE )

5.560 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sage Therapeutic Com

< Previous 1 2 3 4 5 6 Next >
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) INVESTOR ALERT: Investors With Large Losses in Sage Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
Stockholder Notice: Robbins LLP Informs Stockholders of the Class Action Filed Against Sage Therapeutics, Inc.
From Robbins LLP
Via GlobeNewswire
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
From Sage Therapeutics
Via Business Wire
Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Participate in Upcoming May Investor Conferences
From Sage Therapeutics
Via Business Wire
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at Upcoming March Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Changes to Board of Directors
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
From Sage Therapeutics, Inc.
Via Business Wire
5 Biotech stocks tapping into unmet mental health treatment needs
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments. 
Via MarketBeat
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
From Sage Therapeutics, Inc.
Via Business Wire
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
From Biogen Inc.
Via GlobeNewswire
Sage Therapeutics to Present at Upcoming November Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at Upcoming September Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating DigitalOcean, and Sage and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.